Differentiating Axial Disease in PsA Versus AS With Psoriasis Differentiating Axial Disease in PsA Versus AS With Psoriasis
Some identifiers of patients with isolated axial psoriatic arthritis were older age at diagnosis, psoriatic nail lesions, and absence of inflammatory back pain.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 9, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
FDA Approves Sotyktu (deucravacitinib) for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 9, 2022 Category: Drugs & Pharmacology Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
First Approved Treatment for Generalized Pustular Psoriasis
(MedPage Today) -- The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced.
The approval stipulates use of the drug to treat GPP flares in... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 7, 2022 Category: American Health Source Type: news
FDA Approves SPEVIGO for Generalized Pustular Psoriasis Flares
TUESDAY, Sept. 6, 2022 -- The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
SPEVIGO is a novel, selective antibody infusion that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 6, 2022 Category: Pharmaceuticals Source Type: news
Diagnosis of Psoriasis May Be Delayed in Primary Care
TUESDAY, Sept. 6, 2022 -- Psoriasis diagnoses in primary care may be delayed by up to five years, according to an observational study published online Aug. 30 in the British Journal of General Practice.
Maha Abo-Tabik, from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 6, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Spevigo (spesolimab-sbzo) for Generalized Pustular Psoriasis (GPP) Flares in Adults
More than half of patients treated with Spevigo (spesolimab-sbzo) injection, for intravenous use showed no visible pustules one week after receiving treatment
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 3, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Okays First Treatment for Generalized Pustular Psoriasis FDA Okays First Treatment for Generalized Pustular Psoriasis
Spesolimab, a selective monoclonal antibody that blocks interleukin-36 receptors, had received orphan drug and breakthrough therapy designation and underwent priority review.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2022 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news
Asian Patients With Psoriasis Have Shortest Visits, Study Shows Asian Patients With Psoriasis Have Shortest Visits, Study Shows
Dermatologists spent less time with Asian patients with psoriasis than patients of other races and ethnicities, the study investigators reported.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 25, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
Strictly star Aljaž Škorjanec on his 'frustrating' condition - 'It was really difficult'
FORMER Strictly Come Dancing professional Alja Š korjanec has never seemed to have any issue with confidence, on and off the dance floor. But this Psoriasis Awareness Month, fans are reminded of the Solvenian born ballroom dancer's battle with the itchy condition. More recently the star has also shared his top tips for what helps him overcome his symptoms. (Source: Daily Express - Health)
Source: Daily Express - Health - August 21, 2022 Category: Consumer Health News Source Type: news
Psoriasis: The best type of food to alleviate condition – symptoms to spot
PSORIASIS is a painful skin condition which causes the skin to form flaky patches of skin. The condition, which can appear on any part of the body, can vary in severity but can take months to clear. Express.co.uk has been speaking to nutritionist Melissa Snover about the best foods to eat to help alleviate symptoms and the ones to miss to avoid a flare-up. (Source: Daily Express - Health)
Source: Daily Express - Health - August 20, 2022 Category: Consumer Health News Source Type: news
Comorbidities Up Among Patients With ESRD, Concomitant Psoriasis
WEDNESDAY, Aug. 17, 2022 -- For patients with end-stage renal disease (ESRD), those with concomitant psoriasis are younger and more often have cancer, diabetes mellitus, and coronary artery disease, according to a study published online July 26 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 17, 2022 Category: Pharmaceuticals Source Type: news
Paradoxical Psoriasis: A Consequence of TNF Antagonists in IBD Paradoxical Psoriasis: A Consequence of TNF Antagonists in IBD
This paper presents a practical overview of TNF antagonist-associated psoriasis in patients with inflammatory bowel disease. Which patients are most at risk, and how should management be approached?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Nerve Block Plus Lidocaine Clears Psoriasis in Small Study
Title: Nerve Block Plus Lidocaine Clears Psoriasis in Small StudyCategory: Health NewsCreated: 8/15/2022 12:00:00 AMLast Editorial Review: 8/16/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 16, 2022 Category: Dermatology Source Type: news
Nerve Block Plus Lidocaine Clears Psoriasis in Small Study
MONDAY, Aug. 15, 2022 -- Spinal injections of a common anesthetic may help clear the inflammatory skin condition psoriasis, a small pilot study suggests.
The study involved four patients with severe psoriasis, and researchers are describing it as a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 15, 2022 Category: General Medicine Source Type: news
